Live attenuated vaccine: The first clinically approved dengue vaccine?

Katja Fink, Pei Yong Shi

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. There are 390 million human infections each year, with 96 million infections exhibiting disease symptoms. Currently, there is no clinically approved vaccine and antiviral for DENV. The four serotypes of DENV (DENV-1, -2, -3 and -4) have 25-40% variation at the amino acid level. Such variation has posed challenges for the development of a tetravalent vaccine and therapeutics.

Original languageEnglish (US)
Pages (from-to)185-188
Number of pages4
JournalExpert review of vaccines
Issue number2
StatePublished - Feb 2014


  • T cells
  • antibodies
  • dengue
  • live-attenuated
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Live attenuated vaccine: The first clinically approved dengue vaccine?'. Together they form a unique fingerprint.

Cite this